Literature DB >> 23771004

The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT.

S P Robinson1, C Canals, J J Luang, H Tilly, C Crawley, J Y Cahn, D Pohlreich, S Le Gouill, M Gilleece, N Milpied, M Attal, P Biron, S Maury, A Rambaldi, J Maertens, S Capria, P Colombat, S Montoto, A Sureda.   

Abstract

Both auto-SCT and reduced intensity allo-SCT (RIST) are employed in the treatment of relapsed follicular lymphoma (FL). We have analysed the outcome of these two transplant procedures when used as a first transplant in this setting. We conducted a retrospective comparison of 726 patients who underwent an auto-SCT and 149 who underwent a RIST as a first transplant procedure for relapsed FL as reported to the Lymphoma Working Party of the European Bone Marrow Transplant. The non-relapse mortality (NRM) was significantly worse for patients undergoing a RIST (relative risk (RR) 4.0, P<0.001). The 1-year NRM was 15% for those undergoing a RIST compared with 3% for those undergoing an auto-SCT. Disease relapse or progression were significantly worse for those receiving an auto-SCT (RR 3.1, P<0.001). Patients undergoing a RIST had a 5-year relapse rate of 20% compared with 47% for those undergoing an auto-SCT. The PFS at 5 years was 57% for patients receiving a RIST compared with 48% for those receiving an auto-SCT. There was no significant difference in OS between the two groups. RIST is associated with a higher NRM and lower relapse rate in patients with relapsed FL.

Entities:  

Mesh:

Year:  2013        PMID: 23771004     DOI: 10.1038/bmt.2013.83

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  22 in total

1.  Transplantation in follicular lymphoma: not "yes or no" but "whom and when".

Authors:  Georg Hess; Ralf Georg Meyer
Journal:  Haematologica       Date:  2013-09       Impact factor: 9.941

2.  Pretransplantation fluorine-18-deoxyglucose-positron emission tomography scan has no influence on relapse and survival in non-Hodgkin lymphoma patients undergoing allo-SCT.

Authors:  V Bachanova; Q Cao; C Ustun; A T K Kendi; J Froelich; A Lazaryan; L J Burns
Journal:  Bone Marrow Transplant       Date:  2014-09-29       Impact factor: 5.483

3.  Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma.

Authors:  S Yano; T Mori; Y Kanda; J Kato; C Nakaseko; S Fujisawa; N Tomita; R Sakai; K Shono; T Saitoh; N Aotsuka; N Kobayashi; T Saito; S Takahashi; H Kanamori; S Okamoto
Journal:  Bone Marrow Transplant       Date:  2015-07-13       Impact factor: 5.483

4.  Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.

Authors:  Anna Sureda; Mei-Jie Zhang; Peter Dreger; Jeanette Carreras; Timothy Fenske; Herve Finel; Harry Schouten; Silvia Montoto; Stephen Robinson; Sonali M Smith; Ariane Boumedil; Mehdi Hamadani; Marcelo C Pasquini
Journal:  Cancer       Date:  2018-02-09       Impact factor: 6.860

5.  Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party.

Authors:  K Horstmann; A Boumendil; J Finke; H Finel; E Kanfer; G Milone; N Russell; A Bacigalupo; Y Chalandon; J L Diez-Martin; N Ifrah; M Jurado Chacon; P Dreger
Journal:  Bone Marrow Transplant       Date:  2015-03-09       Impact factor: 5.483

6.  Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?

Authors:  Mehdi Hamadani; Mary M Horowitz
Journal:  J Oncol Pract       Date:  2017-12       Impact factor: 3.840

7.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

Authors:  Carla Casulo; Michelle Byrtek; Keith L Dawson; Xiaolei Zhou; Charles M Farber; Christopher R Flowers; John D Hainsworth; Matthew J Maurer; James R Cerhan; Brian K Link; Andrew D Zelenetz; Jonathan W Friedberg
Journal:  J Clin Oncol       Date:  2015-06-29       Impact factor: 44.544

8.  Where does transplant fit in the age of targeted therapies?

Authors:  Victor A Chow; Ajay K Gopal
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

9.  Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.

Authors:  Evgeny Klyuchnikov; Ulrike Bacher; Nicolaus M Kröger; Parameswaran N Hari; Kwang Woo Ahn; Jeanette Carreras; Veronika Bachanova; Asad Bashey; Jonathon B Cohen; Anita D'Souza; César O Freytes; Robert Peter Gale; Siddhartha Ganguly; Mark S Hertzberg; Leona A Holmberg; Mohamed A Kharfan-Dabaja; Andreas Klein; Grace H Ku; Ginna G Laport; Hillard M Lazarus; Alan M Miller; Alberto Mussetti; Richard F Olsson; Shimon Slavin; Saad Z Usmani; Ravi Vij; William A Wood; David G Maloney; Anna M Sureda; Sonali M Smith; Mehdi Hamadani
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-04       Impact factor: 5.742

Review 10.  Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.

Authors:  Timothy S Fenske; Mehdi Hamadani; Jonathon B Cohen; Luciano J Costa; Brad S Kahl; Andrew M Evens; Paul A Hamlin; Hillard M Lazarus; Effie Petersdorf; Christopher Bredeson
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-27       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.